Form 4: Xeris Biopharma CMO Receives Significant Equity Grants

Xeris Biopharma's Chief Medical Officer, Anh Tu Nguyen, was granted 121,293 restricted stock units and 162,162 stock options, aligning his interests with shareholders.

Summary

• Anh Tu Nguyen, Chief Medical Officer of Xeris Biopharma Holdings, Inc., reported changes in beneficial ownership.
• Acquired 121,293 shares of Common Stock through a restricted stock unit (RSU) grant on January 30, 2026, with a transaction price of $0.
• These RSUs will vest in equal annual installments over three years, contingent on continued employment.
• Acquired 162,162 stock options (right to buy) on January 30, 2026, with an exercise price of $7.36.
• These stock options will vest in equal annual installments over three years, contingent on continued service, and expire on January 30, 2036.
• Beneficial ownership also includes 3,030 shares acquired on December 31, 2025, under the issuer's 2018 Employee Stock Purchase Plan.
• Indirect beneficial ownership includes 3,710 shares held by an IRA and 3,501 shares held by children's IRAs, for which the reporting person disclaims beneficial ownership except to the extent of pecuniary interest.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices that align management incentives with shareholder interests, which is generally favorable for corporate governance and long-term stability.

Positives

• The grant of restricted stock units and stock options aligns the Chief Medical Officer's financial interests with those of the company's shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice for retaining key executives and motivating them to contribute to the company's success.

Industry Context

StockSavvy.ai notes that executive equity grants, such as restricted stock units and stock options, are a common and effective mechanism within the biopharmaceutical industry to attract, retain, and incentivize key talent. This practice ensures that the interests of top management are closely tied to the long-term performance and shareholder value creation of the company, which is particularly crucial in a sector characterized by long development cycles and significant R&D investment.

Comparison to Industry Standards

• The structure of these grants, with vesting over three years, is consistent with typical executive compensation packages in the biopharmaceutical industry, aiming for long-term retention and performance alignment.
• Comparable companies like BioNTech SE or Moderna, Inc. frequently utilize similar equity-based incentives for their executive teams to foster innovation and sustained growth.

Corporate Governance

Stakeholder Impact

• Shareholders: The grants aim to align the Chief Medical Officer's interests with shareholders, potentially leading to better long-term performance and value creation.
• Employees: The grants are part of the company's overall compensation strategy, which can influence employee morale and retention, particularly for key executives.

Next Steps

• The restricted stock units and stock options will vest in equal annual installments over three years, subject to continued employment/service.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation grants, which are a standard practice for aligning management incentives with shareholder interests. While positive for corporate governance and executive retention, it does not present new information that would significantly alter the company's fundamental outlook or warrant a change in investment recommendation. Investors should continue to monitor the company's operational and financial performance.

Keywords

Xeris Biopharma, XERS, Anh Tu Nguyen, Chief Medical Officer, Restricted Stock Units, Stock Options, Insider Transaction, Equity Compensation, Form 4, SEC Filing